Ashish Trivedi, MD
Neurology · Auburn, WANPI 1134177413
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Lilly USA, LLC at 32.9% of the total. Reporting peaked in 2020 at $35,686 and has fallen 89.7% since, to $3,680 in 2025. Among neurology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,441 payments — averaging $81.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$38K
- Neurocrine Biosciences, Inc.$17K
- EMD Serono, Inc.$13K
- Bristol Myers Squibb$13K
- SK Life Science, Inc.$6K
- E.r. Squibb & Sons, L.L.C.$6K
- plus $24K from 54 others
Across 11 payments — averaging $5205.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$53K
- Eisai Inc.$5K
What the payments were for
- Consulting fees$43,58137%
- Speaking & faculty fees$38,38633%
- Travel & lodging$10,4639%
- Food & beverage$23,86420%
- Education$5961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,890 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $205,374 |
| Plegridy PenPeginterferon Beta-1a | 11 | $88,996 |
| Aimovig AutoinjectorErenumab-Aooe | 76 | $66,657 |
| Emgality PenGalcanezumab-Gnlm | 62 | $55,415 |
| RytaryCarbidopa/Levodopa | 34 | $50,467 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $32,021 |
| BotoxOnabotulinumtoxina | 26 | $31,511 |
| XcopriCenobamate | 18 | $25,874 |
| OngentysOpicapone | 12 | $22,379 |
| FycompaPerampanel | 14 | $19,030 |
| NeuproRotigotine | 15 | $18,441 |
| RexultiBrexpiprazole | 12 | $17,833 |
| Selegiline Hcl | 113 | $11,122 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 243 | $6,305 |
| Sumatriptan Succinate | 52 | $6,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $17,321 | $227,75435 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil | $478 | $54,31660 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $92 | $32,02121 claims |
| AbbVieBotox | $1,612 | $31,51126 claims |
| SK Life Science, Inc.Xcopri | $6,271 | $25,87418 claims |
| Eisai Inc.Fycompa | $397 | $19,03014 claims |
| UCB, Inc.Neupro | $533 | $18,44115 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $232 | $17,83312 claims |
| Upsher-smith Laboratories LLCTopiramate | $21 | $1,39081 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,277 | $93311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 neurology providers in Washington.
Other neurology in Auburn
- Pavle RepovicSeattle$1.1M
- Jason AldredSpokane$1M
- Pinky AgarwalKirkland$795K
- Stacy DonlonTacoma$613K
- Nathaniel WatsonSeattle$486K
- James BowenKirkland$379K
- Christyn EdmundsonSeattle$318K
- Jessica CraddockSpokane$266K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.